300 related articles for article (PubMed ID: 35426060)
1. The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.
Cohen F; Yuan H; DePoy EMG; Silberstein SD
Neurotherapeutics; 2022 Apr; 19(3):922-930. PubMed ID: 35426060
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.
Cohen F; Yuan H; Silberstein SD
BioDrugs; 2022 May; 36(3):341-358. PubMed ID: 35476215
[TBL] [Abstract][Full Text] [Related]
4. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
Tringali G; Navarra P
Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
[TBL] [Abstract][Full Text] [Related]
5. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
Levin M; Silberstein SD; Gilbert R; Lucas S; Munsie L; Garrelts A; Kennedy K; Everman N; Pearlman E
Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
[TBL] [Abstract][Full Text] [Related]
6. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
7. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
Jiang Y; Huang ZL
Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
Bigal ME; Walter S
CNS Drugs; 2014 May; 28(5):389-99. PubMed ID: 24638916
[TBL] [Abstract][Full Text] [Related]
10. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M
Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515
[TBL] [Abstract][Full Text] [Related]
11. Treatment of migraine with monoclonal antibodies.
Serra López-Matencio JM; Gago-Veiga AB; Gómez M; Alañón Plaza E; Mejía GP; González-Gay MÁ; Castañeda S
Expert Opin Biol Ther; 2022 Jun; 22(6):707-716. PubMed ID: 35502612
[TBL] [Abstract][Full Text] [Related]
12. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
13. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
14. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
Raffaelli B; Reuter U
Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
[TBL] [Abstract][Full Text] [Related]
15. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.
Yuan H; Lauritsen CG; Kaiser EA; Silberstein SD
BioDrugs; 2017 Dec; 31(6):487-501. PubMed ID: 29116598
[TBL] [Abstract][Full Text] [Related]
16. The sense of stopping migraine prophylaxis.
Al-Hassany L; Lyons HS; Boucherie DM; Farham F; Lange KS; Marschollek K; Onan D; Pensato U; Storch E; Torrente A; Waliszewska-Prosół M; Reuter U;
J Headache Pain; 2023 Feb; 24(1):9. PubMed ID: 36792981
[TBL] [Abstract][Full Text] [Related]
17. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Favoni V; Giani L; Al-Hassany L; Asioli GM; Butera C; de Boer I; Guglielmetti M; Koniari C; Mavridis T; Vaikjärv M; Verhagen I; Verzina A; Zick B; Martelletti P; Sacco S;
J Headache Pain; 2019 Mar; 20(1):27. PubMed ID: 30866804
[TBL] [Abstract][Full Text] [Related]
18. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
19. Erenumab in the treatment of migraine.
Jain S; Yuan H; Spare N; Silberstein SD
Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
[TBL] [Abstract][Full Text] [Related]
20. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
Dodick DW
Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
